SWTX SpringWorks Therapeutics, Inc. Forward P/S Multiple

The projected P/S metric clearly captures investor sentiment swings, with the parameter value standing at 16.00. SpringWorks Therapeutics (SWTX) remains completely insulated from economic downturns due to the high value of its oncology drugs. Demand for specialized treatment is independent of macroeconomic indicators, relying instead on clinical success. Patent protection secures the company's pioneer status, eliminating pressure from low-cost generics.

SWTX (springworkstx.com) Price to Expected Revenue Ratio history from 03/01/2024 to 07/12/2025

SpringWorks Therapeutics, Inc - analytical breakdowns and key metrics (SWTX)

- current price and projected stock value:

Stock Price SpringWorks Therapeutics, Inc.|SWTX - Analyst Target Range

- market capitalization data:

Market Capitalization SpringWorks Therapeutics, Inc|SWTX - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share SpringWorks Therapeutics|SWTX - Total Net Assets|Market Capitalization to Book Value Ratio springworkstx.com|SWTX - Company Assets

- debt and liquidity data:

Total Debt to Capital SpringWorks Therapeutics|SWTX - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio SpringWorks Therapeutics|SWTX - Aggregate Debt Obligations|Debt to Book Value SpringWorks Therapeutics, Inc|SWTX - Amount of Long-Term Liabilities|Company Short-Term Debts SpringWorks Therapeutics|Quick Ratio springworkstx.com

- net income and valuation multiples indicators:

SWTX - Company Net Income|Expected Profit SpringWorks Therapeutics|SWTX - Company Value to Net Income|Forward P/E Multiple SpringWorks|SWTX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SpringWorks Therapeutics, Inc|SWTX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months SpringWorks Therapeutics|SWTX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months springworkstx.com|SWTX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year SpringWorks Therapeutics

- issuer revenue and sales details:

SWTX - Company Annual Revenue|Company Projected Revenue SpringWorks Therapeutics, Inc.|SWTX - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple SpringWorks Therapeutics, Inc

Summary company analysis:SpringWorks Therapeutics, Inc. (SWTX)

The market assesses the investment potential of SpringWorks Therapeutics (SWTX) through the lens of expected revenue, where the current value of 16.00 reflects the cost of one dollar of future sales. By analyzing the forward P/S history, an investor can see how the full utilization of partner capacities for oncology drug production converts into the market value of this high-risk biopharmaceutical asset.

Competing companies